CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin

Blood

Volumn 107, Issue 1, 2006, Pages 373-380

  Schaer, Dominik J ^a   Schaer, Christian A ^b   Buehler, Paul W ^b   Boykins, Robert A ^b   Schoedon, Gabriele ^b   Alayash, Abdu I ^b   Schaffner, Andreas ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; CD163 ANTIGEN; CELL RECEPTOR; CYSTEINE; HAPTOGLOBIN; HEME OXYGENASE; HEMOGLOBIN; MESSENGER RNA;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; ENDOCYTOSIS; ENDOSOME; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; MOLECULAR WEIGHT; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN TRANSPORT;

EID: 30144435054     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1014     Document Type: Article

References (39)

1. Wagener FADTG, van Beurden HE, von den Hoff JW, Adema GJ, Figdor CG. The heme-heme oxygenase system: a molecular switch in wound healing. Blood. 2003;102:521-528.
2. Jeney V, Balla J, Yachie A, et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood. 2002;100:879-887.
3. Liu X, Spolarics Z. Methemoglobin is a potent activator of endothelial cells by stimulating IL-6 and IL-8 production and E-selectin membrane expression. Am J Physiol Cell Physiol. 2003;285:C1036-C1046.
4. Graca-Souza AV, Arruda MAB, de Freitas MS, Barja-Fidalgo C, Oliveira PL. Neutrophil activation by heme: implications for inflammatory processes. Blood. 2002;99:4160-4165.
5. Alayash AI. Oxygen therapeutics: can we tame haemoglobin? Nat Rev Drug Discov. 2004;3:152-159.
6. Bleeker WK, Berbers GA, den Boer PJ, Agterberg J, Rigter G, Bakker JC. Effect of polymerization on clearance and degradation of free hemoglobin. Biomater Artif Cells Immobilization Biotechnol. 1992;20:747-750.
7. Law SK, Micklem KJ, Shaw JM, et al. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur J Immunol. 1993;23:2320-2325.
8. Zwadlo G, Voegeli R, Osthoff KS, Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol. 1987;55:295-304.
9. Schaer DJ, Boretti FS, Hongegger A, et al. Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics. 2001;53:170-177.
10. Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6-10.
11. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
12. Madsen M, Moller HJ, Nielsen MJ, et al. Molecular characterization of the haptoglobin-hemoglobin receptor CD163: ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem. 2004;279:51561-51567.
13. Moestrup SK, Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 2004;36:347-354.
14. Djemadji-Oudjiel N, Goerdt S, Kodelja V, Schmuth M, Orfanos CE. Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1 + 3, MS-1 +/-, 25F9-) in psoriatic dermis. Arch Dermatol Res. 1996;288:757-764.
15. Hogger P, Erpenstein U, Rohdewald P, Sorg C. Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 1998;15:296-302.
16. Schaer DJ, Boretti FS, Schoedon G, Schaffner A. Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br J Haematol. 2002;119:239-243.
17. Sulahian TH, Hogger P, Wahner AE, et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine. 2000;12:1312-1321.
18. Tabbara IA. Hemolytic anemias: diagnosis and management. Med Clin North Am. 1992;76:649-668.
19. Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA. 1980;243:1909-1911.
20. Anderton R. Hemolysis and haptoglobin levels. N Engl J Med. 1971;284:1044.
21. Rougemont A, Dumbo O, Bouvier M, et al. Hypohaptoglobinaemia as an epidemiological and clinical indicator for malaria: results of two studies in a hyperendemic region in West Africa. Lancet. 1988;2:709-712.
22. Trape JF, Fribourg-Blanc A. Ahaptoglobinemia in African populations and its relation to malaria endemicity. Am J Epidemiol. 1988;127:1282-1288.
23. Lim SK, Kim H, bin Ali A, et al. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood. 1998;92:1870-1877.
24. Tolosano E, Fagoonee S, Hirsch E, et al. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis. Blood. 2002;100:4201-4208.
25. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589-1600.
26. Fagoonee S, Gburek J, Hirsch E, et al. Plasma protein haptoglobin modulates renal iron loading. Am J Pathol. 2005;166:973-983.
27. Hiss S, Mielenz M, Bruckmaier RM, Sauerwein H. Haptoglobin concentrations in blood and milk after endotoxin challenge and quantification of mammary Hp mRNA expression. J Dairy Sci. 2004;87:3778-3784.
28. Schaffner A, King CC, Schaer D, Guiney DG. Induction and antimicrobial activity of platelet basic protein derivatives in human monocytes. J Leukoc Biol. 2004;76:1010-1018.
29. Boykins RA, Joshi M, Syin C, et al. Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design. Peptides. 2000;2:9-17.
30. Nagel RL, Gibson QH. The binding of hemoglobin to haptoglobin and its relation to subunit dissociation of hemoglobin. J Biol Chem. 1971;246:69-73.
31. Panter SS, Vandegriff KD, Yan PO, Regan RF. Assessment of hemoglobin-dependent neurotoxicity: alpha-alpha crosslinked hemoglobin. Artif Cells Blood Substit Immobil Biotechnol. 1994;22:399-413.
32. Baron JF. Blood substitutes: haemoglobin therapeutics in clinical practice. Crit Care. 1999;3:R99-R102.
33. McCormick DJ, Atassi MZ. Hemoglobin binding with haptoglobin: delineation of the haptoglobin binding site on the alpha-chain of human hemoglobin. J Protein Chem. 1990; 9:735-742.
34. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92:1193-1200.
35. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.
36. Gburek J, Verroust PJ, Willnow TE, et al. Megalin and cubilin are endocytic receptors involved in renal clearance of hemoglobin. J Am Soc Nephrol. 2002;13:423-430.
37. Delanghe J, Langlois M, De Buyzere M. Congenital anhaptoglobinemia versus acquired hypohaptoglobinemia [letter]. Blood. 1998;91:3524.
38. Teye K, Quaye I, Koda Y, et al. A-61C and C-101G Hp gene promoter polymorphisms are, respectively, associated with ahaptoglobinaemia and hypohaptoglobinaemia in Ghana. Clin Genet. 2003;64:439-443.
39. Giblett ER. Haptoglobin types in American Negroes. Nature. 1959;183:192-193.